GlassScriptPhysician profile
Stephanie A Moniz
NPI 1235180688
$3,515.21
in general payments reported to CMS, 2019-2025
26 companies · $49.99 in 2025
The $49.99 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $657 · 2021: $545 · 2022: $920 · 2023: $898 · 2024: $444 · 2025: $49.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,392.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,392.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,396.66 | 2019-2024 | |
| Glaxosmithkline, LLC. | $158.53 | 2023-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $124.91 | 2019-2023 | Wegovy |
| Allergan, INC. | $112.84 | 2019 | |
| Janssen Pharmaceuticals, INC | $87.55 | 2019 | |
| Pfizer INC. | $81.07 | 2019 | |
| Lilly USA, LLC | $70.11 | 2019-2023 | Mounjaro, Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $62.38 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $49.29 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $48.81 | 2023-2024 | Aptiom |
| Mylan Specialty L.P. | $43.72 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $34.28 | 2019-2025 | Trintellix |
| Amgen INC. | $30.31 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $25.91 | 2022-2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.27 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.88 | 2024 | Caplyta |
| Regeneron Healthcare Solutions, INC. | $18.28 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.04 | 2023 | |
| Medtronic, INC. | $15.83 | 2025 | Inceptiv |
| Grifols USA, LLC | $14.13 | 2019 | |
| Ironwood Pharmaceuticals, INC | $14.10 | 2019 | |
| Zyla Life Sciences, INC. | $13.53 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $13.10 | 2024 | Nuedexta |
| Astrazeneca Pharmaceuticals LP | $13.00 | 2019 | |
| Astellas Pharma US INC | $11.93 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Moniz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.